No. Patients Taking Various DMARD | No. Patients Showing Malignancies (%) | Site and Type of Malignancies (no. patients) |
---|---|---|
159; MTX | 15 (4.6) | Squamous cell skin carcinoma (2); breast cancer (2); meningioma (2); colon-rectum carcinoma (1); kidney carcinoma (1); ovarian cancer (1); prostate cancer (1); non-Hodgkin lymphoma (1); uterine cancer (1); squamous cell carcinoma of the tongue (1); seminoma (1); papillary thyroid carcinoma (1) |
80; SSZ | 5 (1.5) | Bladder cancer (2); breast carcinoma (2); uterine cancer (1) |
25; CSA | 1 (0.3) | Squamous cell skin carcinoma (1) |
21; LEF | 3 (0.9) | Carcinoid (2); meningioma (1) |
4; AZA | 1 (0.3) | Breast cancer (1) |
15; MTX plus SSZ | 3 (0.9) | Melanoma (2); colon-rectum carcinoma (1) |
9; MTX plus AZA | 2 (0.6) | Melanoma (2) |
5; MTX plus CSA | 1 (0.3) | Seminoma (1) |
4; MTX plus LEF | 1 (0.3) | Breast cancer (1) |
PsA: psoriatic arthritis; DMARD: disease-modifying antirheumatic drug; MTX: methotrexate; SSZ: sulfasalazine; CSA: cyclosporine; LEF: leflunomide; AZA: azathioprine.